Cobalamin deficiency in primary care: a placebocontrolled, double-blind, randomized trial

Submission date	Recruitment status	Prospectively registered
29/12/2005	No longer recruiting	☐ Protocol
Registration date 20/02/2006	Overall study status Completed	Statistical analysis plan
		[X] Results
Last Edited	Condition category	[] Individual participant data
27/01/2011	Nutritional, Metabolic, Endocrine	

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Bernard Favrat

Contact details

Bugnon 44 Lausanne Switzerland 1011 +41 (0)21 314 4906 bernard.favrat@hospvd.ch

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers N/A

Study information

Scientific Title

Study objectives

To evaluate the clinical and biological impact of oral vitamin B12 therapy among patients with a serum vitamin B12 level below 200 pmole/l

Ethics approval required

Old ethics approval format

Ethics approval(s)

The study was approved by the Ethical Review Committee for Clinical Research, Department of Internal Medicine, University of Lausanne, Switzerland

Study design

Placebo-controlled, double-blind, randomized trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Cobalamin deficiency

Interventions

Oral vitamin B12 versus placebo

Intervention Type

Supplement

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Oral vitamin B12

Primary outcome measure

Evolution of biological markers (serum vitamin B12 level, serum methymalonic acid and homocystein levels)

Secondary outcome measures

Clinical evolution (hematologic, neurologic, psychiatric)

Overall study start date

01/01/2004

Completion date

31/12/2005

Eligibility

Key inclusion criteria

Patients suspected of cobalamin deficiency with serum vitamin B12 level between 125 and 200 pmole/l. Patients with serum vitamin B12 level below 125 pmole/l were followed-up openly with oral cobalamin.

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

40 (20 in each group)

Key exclusion criteria

Unwillingness to participate

Date of first enrolment

01/01/2004

Date of final enrolment

31/12/2005

Locations

Countries of recruitment

Switzerland

Study participating centre Bugnon 44

Lausanne Switzerland 1011

Sponsor information

Organisation

Medical Outpatient Clinic, University of Lausanne (Switzerland)

Sponsor details

Bugnon 44 Lausanne Switzerland 1011 +41 (0)21 314 4906 bernard.favrat@hospvd.ch

Sponsor type

University/education

ROR

https://ror.org/019whta54

Funder(s)

Funder type

University/education

Funder Name

Medical Outpatient Clinic, University of Lausanne

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?

Results article results 13/01/2011 Yes No